1. Xuanwu Hospital Capital Medical University, Beijing 100053, China； 2.Luhe Hospital Capital Medical University, Beijing 100053, China
{{custom_zuoZheDiZhi}}
{{custom_authorNodes}}
{{custom_bio.content}}
{{custom_bio.content}}
{{custom_authorNodes}}
Collapse
History+
Received
Revised
Published
2011-11-11
2011-11-11
2011-12-05
Issue Date
2011-12-05
Abstract
OBJECTIVE To evaluate the effectiveness and safety of amantadine in Parkinson’s disease.METHODS Cochrane library， Pubmed database， Embase database， ISI database， CBM database， CNKI database， VIP database， Articles Database in computer were searched. Randomized controlled trials (RCT)， systematic review (SR) or Meta analysis of amantadine vs placebo in Parkinson's disease were selected， then quality evaluation and Meta-analysis were performed.The CONCLUSIONs of the included SR and Meta-analysis were taken into consideration. RESULTS There were 9 RCTs of amantadine vs placebo in treating parkinson's disease. The result showed that the efficacy of amantadine was better than placebo [RR 0.14，95% CI (0.06， 0.29)， P<0.000 01]. Amantadine was better than placebo to improve parkinson′s symptoms [RR -3.21，95% CI (-5.88，-0.54)， P=0.02]. When it comes to ADR， there was no significant difference between amantadine and placebo.
ZHO Gui-hong;I Xing-rong;LI Xio-ling;WNG Yu-qin.
Effectiveness and Safety of Amantadine in Parkinson Disease——a Meta-Analysis[J]. Chinese Pharmaceutical Journal, 2011, 46(23): 1847-1850
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] WALKER J E， ALBERS J W， TOURTELLOTTE W W， et al. A qualitative and quantitative evaluation of amantadine in the treatment of Parkinson′s disease [J]. J Chronic Dis， 1972，25（3）：149-182. [2] SAVERY F. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease [J]. Dis Nerv Syst， 1977， 38(8)：605-608. [3] DALLOS V，HEATHFIELD K， STONE P， et al. Allen use of amantadine in Parkinson's disease. Results of a double-blind trial[J]. British Med Med J， 1970, 4（3）：24-26. [4] BARBEAU A， MARS H， BOTEZ M I， et al. Amantadine-HCl (Symmetrel) in the management of Parkinson’s disease： a doubleblind cross-over study[J]. Can Med Assoc J， 1971， 105(1)：42-46. [5] FRANCISCO P，PEDRO B，FRANCISCA S. Amantadine reduces the duration of levodopa-induced dyskinesia： A randomized， double-blind， placebo-controlled study[J]. Paikinsonism Related Disorders， 2005， 11(7)：449-452. [6] VERTHAGEN M L， DEL D P， VAN DEN M P， et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease[J]. Neurology，1998， 50(5)：1323-1326. [7] LUGINGER E， WENNING G K， BOSCH S， et al. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease[J]. Mov Disord， 2000， 15(5)：873-878. [8] SNOW B J， MACDONALD L， MCAULEY D，et al. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease： a double-blind， placebo-controlled study[J]. Clin Neuropharmacol， 2000， 23(2)：82-85. [9] FEHLING C. The effect of adding amantadine to optimum l-dopa dosage in Parkinson's syndrome[J]. Acta Neurol Scand， 1973，49：245-251.
PDF(1418 KB)
